Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…
Clarivate’s Epidemiology’s coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each country…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key retinal vein occlusion patient populations covering 171 countries…
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer has evolved in recent years with the approval of hormonal agents such as Zytiga (Janssen), Xtandi (Pfizer / Astellas),…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Middle East & Africa pharmaceutical markets (Egypt, Nigeria, Saudi Arabia, and…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Asia-Pacific pharmaceutical markets (Australia, Hong Kong, Indonesia, Malaysia…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Americas pharmaceutical markets (Argentina, Canada, Chile, Colombia, and Peru…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major European pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark,…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pemphigus vulgaris patient population covering 171 countries and…
Clarivate Epidemiology’s coverage of Pemphigus vulgaris comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Pemphigus vulgaris…